文献速递糖尿病

临床诊断成人起病1型糖尿病中常规胰岛自身抗体检测有助于识别误分类及成功停用胰岛素的可能性

Routine Islet Autoantibody Testing in Clinically Diagnosed Adult-Onset Type 1 Diabetes Can Help Identify Misclassification and the Possibility of Successful Insulin Cessation.
PubMed 文献 · Diabetes Care · 2022-01-01

前瞻性评估722例临床诊断成人起病1型糖尿病患者中胰岛自身抗体状态与临床遗传特征及C肽变化的关系,24.8%抗体阴性者遗传和C肽特征提示非自身免疫糖尿病比例高,随访中36.6%抗体阴性者改变治疗,22.6%成功停用胰岛素且HbA1c与继续胰岛素者相似。

要点

  • 722例临床诊断成人起病1型糖尿病中24.8%胰岛自身抗体阴性。
  • 抗体阴性组1型糖尿病遗传风险评分较低且C肽年下降较慢。
  • 抗体阴性者随访中22.6%停用胰岛素且HbA1c与继续胰岛素者相似。

核心结论

  • 成人起病临床诊断1型糖尿病中胰岛自身抗体阴性应促使仔细考虑其他糖尿病亚型。
  • 常规检测时抗体阴性与成功停用胰岛素相关。
  • 这些发现支持近期关于成人起病1型糖尿病常规胰岛自身抗体评估的推荐。

研究设计与样本

  • 前瞻性评估722例临床诊断1型糖尿病且糖尿病病程小于12个月的成人(诊断时年龄≥18岁)中胰岛自身抗体状态(GADA、IA-2A和ZNT8A)与临床遗传特征及进展(尿C肽肌酐比年变化)的关系。
  • 在告知受试者及其临床医生抗体结果后评估2年内治疗和血糖变化。

主要发现

  • 722例临床诊断1型糖尿病受试者中24.8%(179例)抗体阴性。
  • 抗体阴性组平均1型糖尿病遗传风险评分为10.85,抗体阳性组为13.09(P<0.001),2型糖尿病为10.12。
  • 抗体阴性组尿C肽肌酐比年变化为-24%,抗体阳性组为-43%(P<0.001)。
  • 中位随访24个月后,抗体阴性受试者中36.6%(164例中60例)发生治疗改变。
  • 抗体阴性受试者中22.6%(164例中37例)停用胰岛素,其HbA1c与继续胰岛素者相似(57.5 vs 60.8 mmol/mol [7.4 vs 7.7%],P=0.4),14.0%(164例中23例)在胰岛素基础上加用辅助药物。

临床怎么用

  • 作者认为成人起病临床诊断1型糖尿病中胰岛自身抗体阴性应促使仔细考虑其他糖尿病亚型。
  • 作者认为常规检测时抗体阴性与成功停用胰岛素相关,这些发现支持近期关于成人起病1型糖尿病常规胰岛自身抗体评估的推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent joint American Diabetes Association and European Association for the Study of Diabetes guidelines recommend routine islet autoantibody testing in all adults newly diagnosed with type 1 diabetes. We aimed to assess the impact of routine islet autoantibody testing in this population. RESEARCH DESIGN AND METHODS: We prospectively assessed the relationship between islet autoantibody status (GADA, IA-2A, and ZNT8A), clinical and genetic characteristics, and progression (annual change in urine C-peptide-to-creatinine ratio [UCPCR]) in 722 adults (≥18 years old at diagnosis) with clinically diagnosed type 1 diabetes and diabetes duration <12 months. We also evaluated changes in treatment and glycemia over 2 years after informing participants and their clinicians of autoantibody results. RESULTS: Of 722 participants diagnosed with type 1 diabetes, 24.8% (179) were autoantibody negative. This group had genetic and C-peptide characteristics suggestive of a high prevalence of nonautoimmune diabetes: lower mean type 1 diabetes genetic risk score (islet autoantibody negative vs. positive: 10.85 vs. 13.09 [P < 0.001] [type 2 diabetes 10.12]) and lower annual change in C-peptide (UCPCR), -24% vs. -43% (P < 0.001).After median 24 months of follow-up, treatment change occurred in 36.6% (60 of 164) of autoantibody-negative participants: 22.6% (37 of 164) discontinued insulin, with HbA1c similar to that of participants continuing insulin (57.5 vs. 60.8 mmol/mol [7.4 vs. 7.7%], P = 0.4), and 14.0% (23 of 164) added adjuvant agents to insulin. CONCLUSIONS: In adult-onset clinically diagnosed type 1 diabetes, negative islet autoantibodies should prompt careful consideration of other diabetes subtypes. When routinely measured, negative antibodies are associated with successful insulin cessation. These findings support recent recommendations for routine islet autoantibody assessment in adult-onset type 1 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Eason RJ, Thomas NJ, Hill AV, et al. Routine Islet Autoantibody Testing in Clinically Diagnosed Adult-Onset Type 1 Diabetes Can Help Identify Misclassification and the Possibility of Successful Insulin Cessation. Diabetes Care. 2022. PMID: 36205650. doi:10.2337/dc22-0623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。